Dual GLP-1/GIP Agonists: A New Frontier in Fertility-Preserving Endometrial Cancer Treatment

Could Dual GLP-1/GIP Agonists Pave the Way for Fertility Preservation?

The field of gynecologic oncology is witnessing a potentially significant advancement in fertility-preserving treatment approaches for endometrial neoplasms with the introduction of tirzepatide, a novel dual GLP-1/GIP receptor agonist. A groundbreaking Phase II clinical trial at Peking Union Medical College Hospital is exploring tirzepatide's role in treating obese or overweight women with endometrial cancer (EC) or atypical hyperplasia (AH) who wish to preserve their fertility. This single-arm study targets a critical patient population, as approximately 25% of EC patients are premenopausal, with 3-5% under age 40, and about 70% of these younger patients have not yet had children at diagnosis. The trial addresses the well-established link between obesity and endometrial cancer, where every 5 kg/m² increase in BMI correlates with a 50% higher EC risk, while also acknowledging the limitations of current fertility-preserving treatments which often lead to weight gain through progestin therapy.

The study will enroll 45 patients aged 18-40 with pathologically confirmed EC or AH who meet specific obesity criteria (BMI ≥28 kg/m² for Chinese patients, or ≥24 kg/m² with at least one weight-related comorbidity). These patients will receive standard fertility-preserving hormonal treatment alongside tirzepatide, which will be administered subcutaneously once weekly, starting at 2.5 mg and potentially increasing to a maintenance dose of 5-15 mg based on individual tolerance and response. Treatment duration will not exceed 52 weeks, aligning with current regulatory guidelines. Throughout the trial, participants will undergo comprehensive assessments including monthly weight and metabolic evaluations, with endometrial sampling every three months to assess pathological response and conduct molecular studies. The primary outcomes include percentage of weight reduction, tumor response rate, and time to complete remission, while secondary outcomes encompass changes in body composition, metabolic parameters, inflammation markers, adverse events, pregnancy outcomes, and tumor recurrence rates.

Do Preclinical Insights Support This Novel Approach?

Pre-clinical evidence supporting this approach comes from animal studies where tirzepatide demonstrated significant effects on both body weight and tumor mass in an obesity-driven EC mouse model. The mechanism appears to involve modulation of glycolysis, fatty acid metabolism, and cytokine production, ultimately inhibiting EC tumor growth. Recent clinical data from the SURMOUNT-5 trial further highlights tirzepatide's superior weight loss efficacy compared to other GLP-1 receptor agonists, with tirzepatide achieving 20.2% weight reduction versus 13.7% with semaglutide over 72 weeks. This pronounced weight loss effect could be particularly beneficial for EC patients, as studies have shown that obese patients who lose less than 10% of their body weight experience poorer treatment response, pregnancy outcomes, and higher recurrence rates compared to those who successfully lose weight. The relationship between obesity and EC involves multiple pathways, including increased visceral fat promoting abnormal endometrial proliferation, elevated aromatase activity enhancing estrogen-induced proliferation, and chronic inflammation contributing to genetic instability.

The trial design includes rigorous follow-up extending to three years post-treatment, with decreasing frequency over time. Statistical analysis will employ descriptive statistics, appropriate parametric and non-parametric tests, and mixed models to handle complex data. The sample size calculation assumes an improvement in complete response rate from the historical 60% to an expected 80%, with 90% power and a significance level of 0.05. An important aspect of the analysis will be comparing outcomes between purely obese individuals and those with obesity-related comorbidities, as these subgroups may respond differently to treatment. Safety monitoring will include close attention to known tirzepatide side effects, which primarily affect the gastrointestinal system and are usually mild to moderate. The study acknowledges potential serious adverse reactions including hypersensitivity, acute kidney injury, gallbladder diseases, pancreatitis, and thyroid C-cell tumors, though these are rare in clinical experience. Additionally, the trial will monitor for complications specific to fertility-preserving EC treatment, such as endometrial thinning or intrauterine adhesions.

Could This Integrated Strategy Transform Clinical Practice?

This innovative approach combining fertility-preserving treatment with pharmacological weight management represents a significant step forward in addressing the complex relationship between obesity and endometrial neoplasms. The trial's comprehensive design, including molecular studies on endometrial samples, may provide valuable insights into the mechanisms by which weight loss affects tumor biology. However, the single-arm, single-center design does present limitations, potentially introducing selection bias and restricting generalizability. The relatively small sample size may also limit the statistical power for detecting differences in secondary outcomes and subgroup analyses. Despite these limitations, the study addresses an important unmet need in managing obesity-driven endometrial neoplastic diseases, particularly for younger women desiring future fertility. Could this integrated approach to addressing both the hormonal and metabolic aspects of endometrial neoplasms establish a new paradigm in fertility-preserving management? How might the molecular insights gained from serial endometrial sampling during treatment inform our understanding of obesity's role in endometrial carcinogenesis and treatment response? These questions may be answered as the trial progresses, with patient recruitment planned to begin in May 2025.

Looking beyond this specific trial, the findings could inform future larger-scale, randomized controlled studies that would provide more definitive evidence on the efficacy of this approach. If successful, this treatment strategy could significantly improve both oncological and reproductive outcomes for a vulnerable patient population caught between cancer treatment needs and fertility preservation desires. What challenges might arise in implementing such a combined approach in broader clinical practice, particularly regarding insurance coverage, patient adherence to dual therapies, and the coordination of oncologic and reproductive medicine specialists? The results of this groundbreaking trial may begin to address these questions while opening new avenues for research into metabolic interventions for gynecologic malignancies. How might the observed metabolic improvements contribute to long-term oncological and reproductive success beyond the immediate tumor response? The answers to these questions could reshape our approach to treating endometrial neoplasms in the context of the growing global obesity epidemic.

Summary

A Phase II clinical trial at Peking Union Medical College Hospital is investigating tirzepatide, a dual GLP-1/GIP receptor agonist, as an adjunct to fertility-preserving treatment for obese or overweight women with endometrial cancer or atypical hyperplasia. The study addresses the critical intersection of obesity and endometrial neoplasms, as approximately 25% of endometrial cancer patients are premenopausal, with 3-5% under age 40, and about 70% of these younger patients have not yet had children at diagnosis. Every 5 kg/m² increase in BMI correlates with a 50% higher endometrial cancer risk, while current fertility-preserving progestin therapies often lead to weight gain, creating a therapeutic paradox. The trial will enroll 45 patients aged 18-40 who will receive standard hormonal treatment alongside weekly subcutaneous tirzepatide injections (2.5-15 mg) for up to 52 weeks. Primary outcomes include weight reduction percentage, tumor response rate, and time to complete remission, while secondary outcomes encompass metabolic parameters, pregnancy outcomes, and recurrence rates. Preclinical evidence from animal models demonstrates tirzepatide's ability to reduce both body weight and tumor mass through modulation of glycolysis, fatty acid metabolism, and cytokine production. Clinical data from the SURMOUNT-5 trial shows tirzepatide achieving superior weight loss (20.2%) compared to semaglutide (13.7%) over 72 weeks, which is particularly relevant since obese endometrial cancer patients who lose less than 10% body weight experience poorer treatment response and higher recurrence rates. The trial design includes comprehensive follow-up extending three years post-treatment, molecular studies on endometrial samples, and rigorous safety monitoring for both tirzepatide-related adverse events and fertility-preservation complications. While the single-arm, single-center design presents limitations regarding selection bias and generalizability, this innovative approach combining fertility preservation with pharmacological weight management addresses an important unmet need in managing obesity-driven endometrial neoplasms in young women desiring future fertility.